50
Participants
Start Date
January 5, 2024
Primary Completion Date
August 3, 2026
Study Completion Date
January 17, 2028
T-DXd
T-DXd (DS8201a) will be administered as an intravenous (IV) infusion, on Day 1 of each 21-day cycle according to the dosage regimens
WITHDRAWN
National Cheng Kung University Hospital, Tainan City
WITHDRAWN
Monash Medical Center, Melbourne
ACTIVE_NOT_RECRUITING
Flinders Medical Center, Bedford Park
RECRUITING
Grand Hôpital de Charleroi, Charleroi
WITHDRAWN
National Taiwan University Hospital, Taipei
RECRUITING
National Cancer Center, Gyeonggi-do
WITHDRAWN
Seoul National University Bundang Hospital, Gyeonggi-do
RECRUITING
Complejo Hospitalario Universitario A Coruña, A Coruña
RECRUITING
Ospedale San Raffaele, Milan
RECRUITING
Duke University - Trent Center, Durham
WITHDRAWN
Hospital Ruber Internacional, Madrid
RECRUITING
Miami Cancer Institute, Miami
RECRUITING
Kyungpook National University Chilgok Hospital, Daegu
WITHDRAWN
Istituto Nazionale Tumori Fondazione G. Pascale, Napoli
RECRUITING
Institut Gustave Roussy, Villejuif
NOT_YET_RECRUITING
Instituto Aericas, Rio de Janeiro
NOT_YET_RECRUITING
A.C. Camargo Cancer Center, São Paulo
NOT_YET_RECRUITING
IBCC Nucleo de Pequisa e Ensino, São Paulo
ACTIVE_NOT_RECRUITING
Rabin Medical Center, Petah Tikva
RECRUITING
National Cancer Center Hospital, Chūō
RECRUITING
Seoul National University Hospital, Jongno-gu
RECRUITING
Severance Hospital, Yonsei University, Seoul
RECRUITING
Asan Medical Center, Seoul
RECRUITING
Samsung Medical Center, Seoul
RECRUITING
Hospital Universitari Vall d'Hebron, Barcelona
NOT_YET_RECRUITING
Hospital Universitari Dexeus, Distrito de Les Corts
RECRUITING
ICO l'Hospitalet - Hospital Duran i Reynals, L'Hospitalet de Llobregat
WITHDRAWN
Royal Surrey County Hospital, Guildford
Lead Sponsor
Collaborators (1)
AstraZeneca
INDUSTRY
Daiichi Sankyo
INDUSTRY